

# Role of the P2Y<sub>6</sub> receptor of UDP in the modulation of murine dendritic cell functions and Th1 polarisation of the immune response

Dorothee Cammarata<sup>1</sup>, Abduehakem Ben Addi<sup>1</sup>, Eva D'Amico<sup>1</sup> and Bernard Robaye<sup>1\*</sup>

<sup>1</sup> Institute of Interdisciplinary Research in Human and Molecular Biology, Université Libre de Bruxelles, Gosselies 6041, Belgium

<sup>2</sup> Laboratories Center of Excellence, Erasme Hospital, Université Libre de Bruxelles, Brussels, 1070, Belgium

**Abstract:** Numerous studies have demonstrated the role of uridine diphosphate (UDP) and its P2Y<sub>6</sub> receptor in the inflammatory reaction and innate immunity. However, the importance of the P2Y<sub>6</sub> receptor in the adaptive immune response remains unclear. In this study, we demonstrate that the P2Y<sub>6</sub> receptor is functionally expressed in murine bone marrow dendritic cells (BMDC). UDP induced a Ca<sup>2+</sup> transient in these cells that was decreased in P2Y<sub>6</sub>-deficient mice. UDP also increased the endocytosis of fluorescein isothiocyanate-dextran (FITC-dextran) and amplified the secretion of interleukin 12-p70 (IL-12p70) induced by CpG; these responses were abolished in P2Y<sub>6</sub>-deficient mice. *In vivo* experiments showed that the serum level of specific IgG2c after immunisation with ovalbumin was decreased in P2Y<sub>6</sub>-deficient mice, while the level of specific IgG1 was unchanged. These data suggest that the P2Y<sub>6</sub>-mediated effects of UDP on myeloid dendritic cells play a role in the *in vivo* Th1 skewing of the immune response.

**Keywords:** adaptive immunity, dendritic cells, UDP, P2Y<sub>6</sub> receptor

\*Correspondence to: Bernard Robaye, Institute of Interdisciplinary Research in Human and Molecular Biology, Free University of Brussels (ULB), Gosselies 6041, Belgium; Email: [brobaye@ulb.ac.be](mailto:brobaye@ulb.ac.be)

**Received:** April 19, 2016; **Accepted:** June 14, 2016; **Published Online:** July 28, 2015

**Citation:** Cammarata D, Ben Addi A, D'Amico E, *et al.* 2016, Role of the P2Y<sub>6</sub> receptor of UDP in the modulation of murine dendritic cell functions and Th1 polarisation of the immune response. *Journal of Medicines Development Sciences*, vol.2(1):52-59. <http://dx.doi.org/10.18063/JMDS.2016.01.002>.

## 1. Introduction

An increasing number of studies have shown that extracellular nucleotides and nucleosides modulate the inflammatory reaction and the immune response by a variety of mechanisms<sup>[1-3]</sup>. Adenosine triphosphate (ATP) and other nucleotides are now considered as danger signals or Damage Associated Molecular Patterns (DAMPs) that are released from injured or stressed cells by a variety of mechanisms including cell lysis, exocytosis of secretory granules and efflux through channels like con-

nexins and pannexins<sup>[4,5]</sup>. Extracellular ATP modulates cell responses in an autocrine or paracrine way through the activation of the P2X receptors, which are nucleotide-gated ion channels, or of the G protein-coupled P2Y receptors<sup>[6,7]</sup>. ATP is degraded by ectonucleotidases into adenosine diphosphate (ADP) and later, adenosine, that also modulate the immune response through the P2Y<sub>12</sub> receptor and the A<sub>1</sub>, A<sub>2</sub> and A<sub>3</sub> receptors, respectively<sup>[1,8]</sup>.

Uridine nucleotides are also important and an increasing number of studies have demonstrated the role of uridine diphosphate (UDP) and its P2Y<sub>6</sub> receptor in

the inflammatory reaction and the immune response. The P2Y<sub>6</sub> receptor plays a role in the activation of monocytes/macrophages<sup>[9-12]</sup>, microglial phagocytosis<sup>[13,14]</sup>, secretion of various cytokines and chemokines from epithelial and other cells<sup>[15-21]</sup> and activation of microvascular endothelial cells during vascular inflammation<sup>[22]</sup>. The role of UDP and P2Y<sub>6</sub> receptors in adaptive immunity is less clear and apparently more complex. UDP has been shown to activate myeloid dendritic cells<sup>[23,24]</sup>, but it is unclear if this action is mediated by the P2Y<sub>6</sub> receptor, since immature dendritic cells express the P2Y<sub>14</sub> receptor<sup>[25]</sup>, which is also responsive to UDP<sup>[26,27]</sup>. The P2Y<sub>6</sub> receptor is also expressed in plasmacytoid dendritic cells, where UDP inhibits the production of interferon- $\alpha$ <sup>[28,29]</sup>. Expression of the P2Y<sub>6</sub> receptor has also been detected in activated CD4<sup>+</sup> lymphocytes<sup>[30,31]</sup>. It has been reported that activation of murine T cells by T cell receptor (TCR) stimulation is inhibited by a P2Y<sub>6</sub> antagonist<sup>[32]</sup>, while a study on P2Y<sub>6</sub>-deficient mice showed that the absence of P2Y<sub>6</sub> receptor on CD4<sup>+</sup> cells, but not antigen presenting cells, amplified the production of cytokines in a model of allergic pulmonary inflammation<sup>[31]</sup>.

The aim of the present study was to clarify the roles of the P2Y<sub>6</sub> receptor in the activation of myeloid dendritic cells and their *in vivo* impact in a model of immunisation, using P2Y<sub>6</sub>-deficient mice previously generated in our laboratory<sup>[10]</sup>. Our results show that the P2Y<sub>6</sub> receptor controls the biology of dendritic cells and that its expression is required for optimal IgG2c production *in vivo*.

## 2. Materials and Methods

### 2.1 Reagents

UDP, ionomycin, ovalbumin and fluorescein isothiocyanate-dextran (FITC-dextran, 40 kDa) were purchased from Sigma-Aldrich. Fluo-4AM was purchased from Invitrogen.

### 2.2 Animals

P2Y<sub>6</sub><sup>-/-</sup> mice that we previously generated were crossed with C57BL/6 mice for up to 10 generations<sup>[10]</sup>. All of the mice used in this study were spawned using heterozygous parents and housed in a sanitary protected animal facility.

### 2.3 Ethics Statement

All of the animal studies were authorized by the Ani-

mal Care Use and Review Committee of the Université Libre de Bruxelles (CEBEA IBMM protocol 44).

### 2.4 Dendritic Cells Generation

Bone marrow-derived dendritic cells (BMDC) were generated as previously described by Inaba *et al.*<sup>[33]</sup>. Briefly, bone marrow cells obtained from femur and tibia were cultured for 7 days in complete medium [RPMI 1640 supplemented with 5% FCS (foetal calf serum; MultiCell Technologies, Lincoln, RI), 2 mM L-glutamine, 100 U/mL penicillin, 100  $\mu$ g/mL streptomycin and 50  $\mu$ M 2-mercaptoethanol] supplemented with 20 ng/mL GM-CSF (granulocyte-macrophage colony-stimulating factor; Invitrogen). Culture medium was partly refreshed on day 3 and 5.

### 2.5 Isolation of RNA, Reverse Transcription and PCR

Total RNA was extracted using Tripure reagent (Roche Applied Science, Basel, Switzerland) and quantified on a NanoDrop 1000 (Thermo Fisher Scientific, Waltham, MA). After DNase I treatment (Fermentas, Hanover, Germany), RNA was reverse transcribed using the Revert Aid H Minus M-MuLV Reverse Transcriptase (Fermentas). PCR (29 cycles) were performed using the Qiagen Taq Core Kit. Primer sequences used were HPRT: forward 5'-CCTGCTGGA-TTACATTAAGCACTG-3', reverse 5'-GTCAAGG-GCATATCCAACAACAAAC-3' and P2Y<sub>6</sub>: forward 5'-GGTAGCGCTGGAAGCTAATG-3', reverse 5'-AGGAACACCAAATCTGGCA-3'.

### 2.6 [Ca<sup>2+</sup>]<sub>i</sub> Measurement

[Ca<sup>2+</sup>]<sub>i</sub> was measured in BMDC as described<sup>[34]</sup>. Briefly, freshly isolated BMDC were labelled with the calcium fluorescent dye Fluo-4-AM (5  $\mu$ M) in 250  $\mu$ M (1,2)-diphenyl-4-[phenylsulfinylolethyl]-3,5-pyrazolidin edione and pluronic acid F-127 (100  $\mu$ g/mL). Cell fluorescence was monitored at 37°C, using a Becton Dickinson FACScan Flow Cytometer. Data were analysed with the Winmdi software. Results were expressed as a ratio of the maximal response induced by 300 ng/mL ionomycin added 2 min after agonist stimulation.

### 2.7 Endocytosis

BMDC were stimulated as indicated below in the complete medium described earlier. FITC-dextran (1 mg/mL) and UDP (100 $\mu$ M) were simultaneously added to the cell culture and incubated at 37 °C for 30 min. After 3

washes with cold PBS [phosphate-buffered saline; supplemented with 0.1% bovine serum albumine (BSA) and 0.1% sodium azide], cells were labelled with phycoerythrin conjugated anti-CD11c antibody (eBioscience) and then analysed using a FC500 flow cytometer (Beckman Coulter). Cells incubated with the probe at 4 °C were used as background controls. Trypan blue (0.05%) was used to quench extracellular fluorescence. Data obtained are mean fluorescence intensity (MFI) of CD11c positive cell population.

## 2.8 IL-12p70 Measurement

BMDC were cultured for 24 h in complete medium with CpG ODN 1826 (250 ng/mL) with or without UDP (100 μM). Cell-free supernatants were harvested and IL-12p70 concentration was measured with the Ready-Set-Go enzyme linked immunosorbent assay kits (eBioscience).

## 2.9 Mice Immunization

Mice were injected subcutaneously at the base of the tail with 100 μL of an emulsion (1:1) of incomplete Freund's adjuvant (IFA; Sigma-Aldrich) and ovalbumin (100 μg/mice) and bled 14 days later. Serum was obtained after centrifugation of clotted blood (2–6 h at 4°C). Specific anti-ovalbumin immunoglobulins (Ig) isotypes G1 and G2c were quantified by ELISA (LO-IMEX, Brussels, Belgium). Briefly, 96-well flat-bottom plates were coated with ovalbumin (5 μg/mL in PBS) overnight at 4°C, to quantify ovalbumin-specific IgG. Wells were saturated with 1% BSA in PBS for 1 h at room temperature. Serum samples were diluted in PBS/0.5% BSA and incubated for 2 h at 37°C. Specific IgG subclasses were detected using horseradish peroxidase-conjugated rat anti-mouse IgG1 or IgG2c antibodies (LO-IMEX, Belgium).


## 2.10 Statistical Analysis

Statistical tests were performed using Sigmat Plot, version 13.

## 3. Results

### 3.1 Functional Expression of the P2Y<sub>6</sub> Receptor in Dendritic Cells

We first examined the expression of the P2Y<sub>6</sub> receptor in BMDC. As shown in Figure 1A, in freshly isolated bone marrow cells, we did not detect any expression of the P2Y<sub>6</sub> mRNA. After 3 and 7 days of culture in the presence of GM-CSF (20 ng/mL), we



**Figure 1.** Expression of the P2Y<sub>6</sub> receptor in BMDC. **(A)** RNAs of freshly isolated bone marrow cells (3) or of GM-CSF treated adherent bone marrow cells (2: 3 days; 1: 7 days) were extracted and treated. RT-PCR was performed using specific primers for P2Y<sub>6</sub> or HPRT. bp: base pairs. **(B1)** [Ca<sup>2+</sup>]<sub>i</sub> measurement in BMDC. Cells were loaded with Fluo-4-AM and fluorescence was registered by flow cytometry. After monitoring the basal fluorescence, cells were treated with UDP (100 μM) or ATP (100 μM) as positive control and fluorescence was recorded for 2 min. Then, cells were treated with ionomycin (300 nM) for normalization. The dot plots (time versus FL1 fluorescence) shown are for each condition of one representative experiment out of two. **(B2)** Changes in intracellular calcium concentration in response of UDP or ATP in both genotypes. Each cell preparation has been tested in duplicates or triplicates. Results are shown as box-and-whisker plots of ratios of the maximal response measured after ionomycin treatment (median: bar into the box; most distant values: bars outside the box). \**p* < 0.03 using Holm-Sidak's test for multiple comparisons. ns: not significant.

detected by reverse transcription PCR (RT-PCR) a signal at the expected molecular weight (MW), reflecting the expression of the P2Y<sub>6</sub> mRNA. To check the functionality of the P2Y<sub>6</sub> receptor, we studied via flow cytometry the increase of cytoplasmic calcium concentration after UDP stimulation (Figure 1B). In wild type (WT) BMDC cells, we observed a marked elevation of [Ca<sup>2+</sup>]<sub>i</sub> upon UDP (100 μM) stimulation. This UDP effect was reduced by 50% in P2Y<sub>6</sub><sup>-/-</sup> BMDC while the response to ATP stimulation was not affected. From these data, we can conclude that BMDC express a functional P2Y<sub>6</sub> receptor. The residual Ca<sup>2+</sup> rise detected in P2Y<sub>6</sub>-deficient mice might be due to the activation of the P2Y<sub>14</sub> receptor, a UDP-glucose receptor that is known to be sensitive to UDP in rodents<sup>[26]</sup> and to be expressed in human DCs<sup>[25]</sup>.


### 3.2 Increased Antigen Uptake by BMDC Under P2Y<sub>6</sub> Receptor Stimulation

To characterize the effect of UDP and its receptor on endocytosis, we incubated P2Y<sub>6</sub><sup>+/+</sup> and P2Y<sub>6</sub><sup>-/-</sup> BMDC in complete medium containing FITC-Dextran known to be mainly captured by macropinocytosis<sup>[34]</sup>. The stimulation of wild type BMDC with UDP (100 μM) increased cell fluorescence of CD11c<sup>+</sup> cells by 2.36 ± 0.3-fold (mean ± SD of 7 BMDCs preparations analysed in 4 independent experiments). This UDP effect was abolished in P2Y<sub>6</sub><sup>-/-</sup> BMDC where mean cell fluorescence intensity of UDP-treated CD11c<sup>+</sup> cells was 1.05 ± 0.8-fold of non-treated cells (mean ± SD of 9 BMDCs preparations). The data of one representative experiment are shown in Figure 2.


The involvement of UDP in receptor-mediated endocytosis was also investigated using fluorescent ovalbumin (FITC-OVA) and CpG deoxynucleotide (FITC-CpG) as markers<sup>[35]</sup>. UDP enhanced the uptake of FITC-OVA by 1.21 ± 0.08 (mean ± SD of 6 BMDCs preparations analysed in 3 independent experiments) and that of FITC-CpG by 1.19 ± 0.07-fold (mean ± SD of 5 BMDCs preparations analysed in 2 independent experiments) (data not shown). Again, the stimulatory action of UDP was abolished in knockout BMDC (data not shown).

### 3.3 Increased Production of IL-12p70 by BMDC Under P2Y<sub>6</sub> Receptor Stimulation

IL-12p70 plays a key role in the DC-driven Th1 polarisation of T cells. UDP alone was unable to increase the secretion of IL-12p70 from BMDC (Figure 3). However, the CpG-triggered release of this cytokine



**Figure 2.** Effect of P2Y<sub>6</sub> activation on FITC-Dextran uptake by BMDC. WT and P2Y<sub>6</sub><sup>-/-</sup> BMDC were incubated with FITC-dextran (1 mg/mL) in the presence or absence of UDP (100 μM) for 30 min. Fluorescence of cells was recorded by flow cytometry. Results are shown as box-and-whisker plots of Mean of Fluorescence Intensity (MFI) of CD11c positive cells (median: bar into the box; most distant values: bars outside the box). The data are from one representative experiment out of 3. In this experiment, cell preparations from 2 WT mice and 3 from KO mice have been tested in duplicates or triplicates. \*\*\**p* < 0.001 using the Holm-Sidak test for multiple comparisons. ns: not significant.



**Figure 3.** Effect of P2Y<sub>6</sub> activation on IL-12p70 production by BMDC. WT and P2Y<sub>6</sub><sup>-/-</sup> BMDC were incubated with CpG (250 ng/mL) in the presence or absence of UDP (100 μM) for 24 h. Supernatants were collected for measurement of IL-12p70 production by ELISA. Results are shown as box-and-whisker plots of the IL-12p70 concentration in the cells' supernatants (median: bar into the box; most distant values: bars outside the box). The data are from one representative experiment out of 3. In this experiment, cell preparations from 3 WT mice and 2 from KO mice have been tested in triplicates. \**p* < 0.04 using Dunn's test for multiple comparisons. ns: not significant.

by WT BMDC was amplified by  $1.7 \pm 0.6$ -fold (mean  $\pm$  SD of 5 BMDC preparations). This UDP effect was abolished in P2Y<sub>6</sub><sup>-/-</sup> BMDC where the production of IL-12p70 by UDP+CpG-treated KO BMDC was  $0.8 \pm 0.2$ -fold of the control (mean  $\pm$  SD of 6 BMDC preparations). The data of one representative experiment are shown in Figure 3.

### 3.4 Decreased Production of Anti-ovalbumin IgG2c in P2Y<sub>6</sub><sup>-/-</sup> Mice

To study the involvement of the P2Y<sub>6</sub> receptor in the adaptive immune response *in vivo*, we subcutaneously injected an emulsion of ovalbumin (OVA) in incomplete Freund's adjuvant (IFA) into wild type and P2Y<sub>6</sub> knockout mice. Fourteen days after immunization, we determined the concentration of different anti-OVA immunoglobulins. As shown in Figure 4A, the serum concentration of IgG1 anti-OVA was comparable in P2Y<sub>6</sub><sup>-/-</sup> and P2Y<sub>6</sub><sup>+/+</sup> mice, while the anti-OVA IgG2c concentration was significantly reduced in P2Y<sub>6</sub><sup>-/-</sup> mice (Figure 4B). These results suggest that the P2Y<sub>6</sub> receptor is involved in a Th1 skewing of the adaptive immune response.


## 4. Discussion and Conclusion

UDP has been shown previously to act on myeloid DCs, in which it induced a cytosolic Ca<sup>2+</sup> transient<sup>[23,24]</sup> and chemotaxis<sup>[24]</sup>. However, it was not proven that these actions were mediated by the P2Y<sub>6</sub> receptor. They could have involved the P2Y<sub>14</sub> receptor that is also responsive to UDP<sup>[26,27]</sup> and is expressed

on human immature myeloid DCs<sup>[25]</sup>. Our study with P2Y<sub>6</sub>-deficient mice definitely proves the functional expression of P2Y<sub>6</sub> in myeloid DCs, resulting in increased antigen endocytosis and IL-12p70 secretion. This profile of action is clearly different from that of other nucleotide receptors expressed on DCs. In particular ADP also stimulates antigen endocytosis through the P2Y<sub>12</sub> receptor<sup>[8]</sup>, but this action is not associated with a stimulation of IL-12p70 secretion. Actually, ADP decreased IL-12p70 production through its degradation into adenosine and activation of A<sub>2B</sub> adenosine receptors<sup>[34,37]</sup>. In human myeloid DCs, the P2Y<sub>11</sub> receptor of ATP induces semi-maturation, characterised by an increased expression of co-stimulatory molecules but an inhibition of IL-12p70<sup>[38,39]</sup>. The P2Y<sub>2</sub> receptor of ATP and UTP is mainly involved in DCs chemotaxis<sup>[40]</sup>, whereas the P2X<sub>7</sub> receptor of ATP induces the secretion of IL-1 $\beta$ <sup>[41,42]</sup>.

The P2Y<sub>6</sub>-mediated stimulatory effect of UDP on antigen endocytosis associated with increased IL-12p70 secretion is expected to amplify immunisation *in vivo* with a Th1 skewing. This is supported by the observation of a lower serum level of anti-ovalbumin IgG2c in P2Y<sub>6</sub>-deficient mice immunised against ovalbumin, while the level of specific IgG1 was unaffected. Indeed, a Th2 response is associated with a switching to IgG1, while a Th1 response is associated with switching to IgG2a, or IgG2c in C57BL/6 mice<sup>[43]</sup>.

We postulate that local injection of antigen in adjuvant leads to the local release of UDP driving through the P2Y<sub>6</sub>R a Th1 immune response. Therefore, agonists



**Figure 4.** Immunoglobulin production in WT P2Y<sub>6</sub> and KO P2Y<sub>6</sub> mice. Mice were immunised subcutaneously with an emulsion of IFA and Ovalbumin. After fourteen days, mice were bled and specific anti-OVA IgG1 (A) or IgG2c (B) were determined in serum by ELISA. On the 14 (WT) and 15 (KO) mice immunized, 2 in each group did not respond in terms of IgG2c production (O.D. < 0); they have been discarded from the analysis. Data are expressed as mean  $\pm$  SEM of O.D. from two (A) and three (B) independent experiments. \* $p < 0.04$  using unpaired *t*-test (WT versus P2Y<sub>6</sub> KO are compared at the same dilution). *n* : number of mice.

of this receptor could play the role of adjuvant in case of vaccination directed against intracellular pathogens which require a Th1 cellular response of the immune system.

In conclusion, our study demonstrates that the P2Y<sub>6</sub> receptor of UDP is functionally expressed on murine myeloid dendritic cells, where it mediates a stimulation of antigen endocytosis and IL-12p70 secretion *in vivo*. This last action is expected to result in a Th1 skewing of the immune response, and this is supported by the decreased concentration of specific IgG2c in P2Y<sub>6</sub>-deficient mice.

### Author Contributions

Dorothee Cammarata, Abduehakem Ben Addi, Eva D'Amico and Bernard Robaye were involved in the conception, design, data collection, assembly, analysis and interpretation. Dorothee Cammarata and Abduehakem Ben Addi wrote the manuscript.

### Conflict of Interest and Funding

The authors declare no commercial or financial conflict of interest.

### Acknowledgements

This work was supported by the Interuniversity Attraction Poles Programme — Belgian State — Belgian Science Policy, Fonds de la Recherche Scientifique Médicale of Belgium (n° 3.4542.11), Fonds Van Buuren, Fonds Defay and Fonds National de la Recherche Scientifique (FRIA, Belgium). We thank Dominique Fokan for her excellent help and technical assistance.

### References

1. Junger W G, 2011, Immune cell regulation by autocrine purinergic signaling. *Nature Review Immunology*, vol.11: 201–212.  
<http://dx.doi.org/10.1038/nri2938>
2. Di Virgilio F, Boeynaems J M and Robson SC, 2009, Extracellular nucleotides as negative modulators of immunity. *Current Opinion in Pharmacology*, vol.9(4): 507–513.  
<http://dx.doi.org/10.1016/j.coph.2009.06.021>
3. Idzko M, Ferrari D and Eltzschig H K, 2014, Nucleotide signalling during inflammation. *Nature*, vol.509: 310–317.  
<http://dx.doi.org/10.1038/nature13085>
4. Lazarowski E R, Boucher R C and Harden T K, 2003, Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. *Molecular Pharmacology*, vol.64(4): 785–795.  
<http://dx.doi.org/10.1124/mol.64.4.785>
5. Boeynaems J M, Communi D, Gonzalez N S, et al. 2005, Overview of the P2 receptors. *Seminars in Thrombosis and Hemostasis*, vol.31(2): 139–149.  
<http://dx.doi.org/10.1055/s-2005-869519>
6. Boeynaems J M, Communi D and Robaye B, 2012, Overview of the pharmacology and physiological roles of P2Y receptors. *Wiley Interdisciplinary Reviews: Membrane Transport and Signalling*, vol.1(5): 581–588.  
<http://dx.doi.org/10.1002/wmts.44>
7. Syed N I H and Kennedy C, 2011, Pharmacology of P2X receptors. *Wiley Interdisciplinary Reviews: Membrane Transport and Signalling*, vol.1(1): 16–30.  
<http://dx.doi.org/10.1002/wmts.1>
8. Ben Addi A, Cammarata D, Conley P B, et al. 2010, Role of the P2Y<sub>12</sub> receptor in the modulation of murine dendritic cell function by ADP. *Journal of Immunology*, vol.185(10): 5900–5906.  
<http://dx.doi.org/10.4049/jimmunol.0901799>
9. Warny M, Aboudola S, Robson S C, et al. 2001, P2Y<sub>6</sub> nucleotide receptor mediates monocyte interleukin-8 production in response to UDP or lipopolysaccharide. *Journal of Biological Chemistry*, vol.276: 26051–26056.  
<http://dx.doi.org/10.1074/jbc.M102568200>
10. Bar I, Guns P J, Metallo J, et al. 2008, Knockout mice reveal a role for P2Y<sub>6</sub> receptor in macrophages, endothelial cells, and vascular smooth muscle cells. *Molecular Pharmacology*, vol.74(3): 777–784.  
<http://dx.doi.org/10.1124/mol.108.046904>
11. Kukulski F, Ben Yebdri F, Lefebvre J, et al. 2007, Extracellular nucleotides mediate LPS-induced neutrophil migration *in vitro* and *in vivo*. *Journal of Leukocyte Biology*, vol.81(5): 1269–1275.  
<http://dx.doi.org/10.1189/jlb.1206758>
12. Ben Yebdri F, Kukulski F, Tremblay A, et al. 2009, Concomitant activation of P2Y<sub>2</sub> and P2Y<sub>6</sub> receptors on monocytes is required for TLR1/2-induced neutrophil migration by regulating IL-8 secretion. *European Journal of Immunology*, vol.39(10): 2885–2894.  
<http://dx.doi.org/10.1002/eji.200939347>
13. Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, et al. 2007, UDP acting at P2Y<sub>6</sub> receptors is a mediator of microglial phagocytosis. *Nature*, vol.446: 1091–1095.  
<http://dx.doi.org/10.1038/nature05704>
14. Inoue K., Koizumi S, Kataoka A, et al. 2009, P2Y<sub>6</sub>-evoked microglial phagocytosis. *International Review of Neurobiology*, vol.85: 159–163.  
[http://dx.doi.org/10.1016/S0074-7742\(09\)85012-5](http://dx.doi.org/10.1016/S0074-7742(09)85012-5)
15. Grbic D M, Degagné É, Langlois C, et al. 2008, Intestinal inflammation increases the expression of the P2Y<sub>6</sub> receptor on epithelial cells and the release of CXC chemo-

- kine ligand 8 by UDP. *Journal of Immunology*, vol.180(4): 2659–2668.  
<http://dx.doi.org/10.4049/jimmunol.180.4.2659>
16. Grbic D M, Degagné É, Larrivée J F, *et al.* 2012, P2Y<sub>6</sub> receptor contributes to neutrophil recruitment to inflamed intestinal mucosa by increasing CXC chemokine ligand 8 expression in an AP-1-dependent manner in epithelial cells. *Inflammatory Bowel Diseases*, vol.18(8): 1456–1469.  
<http://dx.doi.org/10.1002/ibd.21931>
  17. Hansen A, Alston L, Tulk S E, *et al.* 2013, The P2Y<sub>6</sub> Receptor mediates *Clostridium difficile* toxin-induced CXCL8/IL-8 production and intestinal epithelial barrier dysfunction. *PLoS ONE*, vol.8(11): e81491.  
<http://dx.doi.org/10.1371/journal.pone.0081491>
  18. Khine A A, Del Sorbo L, Vaschetto R, *et al.* 2006, Human neutrophil peptides induce interleukin-8 production through the P2Y<sub>6</sub> signaling pathway. *Blood*, vol.107: 2936–2942.  
<http://dx.doi.org/10.1182/blood-2005-06-2314>
  19. Vieira R P, Müller T, Grimm M, *et al.* 2011, P2Y<sub>6</sub> receptor contributes to airway inflammation and remodeling in experimental allergic airway inflammation. *American Journal of Respiratory and Critical Care Medicine*, vol.184(2): 215–223.  
<http://dx.doi.org/10.1164/rccm.201011-1762OC>
  20. Uratsugi H, Tada Y, Kawashima T, *et al.* 2012, P2Y<sub>6</sub> receptor signaling pathway mediates inflammatory responses induced by monosodium urate crystals. *Journal of Immunology*, vol.188(1): 436–444.  
<http://dx.doi.org/10.4049/jimmunol.1003746>
  21. Kim B, Jeong H, Kim J, *et al.* 2011, Uridine 5 -diphosphate induces chemokine expression in microglia and astrocytes through activation of the P2Y<sub>6</sub> receptor. *Journal of Immunology*, vol.186(6): 3701–3709.  
<http://dx.doi.org/10.4049/jimmunol.1000212>
  22. Riegel A K, Faigle M, Zug S, *et al.* 2011, Selective induction of endothelial P2Y<sub>6</sub> nucleotide receptor promotes vascular inflammation. *Blood*, vol.117: 2548–2555.  
<http://dx.doi.org/10.1182/blood-2010-10-313957>
  23. Marriott I, Inscho E W and Bost K L, 1999, Extracellular uridine nucleotides initiate cytokine production by murine dendritic cells. *Cellular Immunology*, vol.195(2): 147–156.  
<http://dx.doi.org/10.1006/cimm.1999.1531>
  24. Idzko M, Panther E, Sorichter S, *et al.* 2004, Characterization of the biological activities of uridine diphosphate in human dendritic cells: influence on chemotaxis and CXCL8 release. *Journal of Cellular Physiology*, vol.201(2): 286–293.  
<http://dx.doi.org/10.1002/jcp.20070>
  25. Skelton L, Cooper M, Murphy M, *et al.* 2003, Human immature monocyte-derived dendritic cells express the G protein-coupled receptor GPR105 (KIAA0001, P2Y<sub>14</sub>) and increase intracellular calcium in response to its agonist, uridine diphosphoglucose. *Journal of Immunology*, vol.171(4): 1941–1949.  
<http://dx.doi.org/10.4049/jimmunol.171.4.1941>
  26. Fricks I P, Maddileti S, Carter R L, *et al.* 2008, UDP is a competitive antagonist at the human P2Y<sub>14</sub> receptor. *Journal of Pharmacology and Experimental Therapeutics*, vol.325(2): 588–594.  
<http://dx.doi.org/10.1124/jpet.108.136309>
  27. Carter R L, Fricks I P, Barrett M O, *et al.* 2009, Quantification of G<sub>i</sub>-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y<sub>14</sub> receptor. *Molecular Pharmacology*, vol.76(6): 1341–1348.  
<http://dx.doi.org/10.1124/mol.109.058578>
  28. Shin A, Toy T, Rothenfusser S, *et al.* 2008, P2Y receptor signaling regulates phenotype and IFN- $\alpha$  secretion of human plasmacytoid dendritic cells. *Blood*, vol.111: 3062–3069.  
<http://dx.doi.org/10.1182/blood-2007-02-071910>
  29. Mao C, Wang S, Xiao Y, *et al.* 2011, Impairment of regulatory capacity of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves' disease. *Journal of Immunology*, vol.186(8): 4734–4743.  
<http://dx.doi.org/10.4049/jimmunol.0904135>
  30. Somers G R, Hammet F M, Trute L, *et al.* 1998, Expression of the P2Y<sub>6</sub> purinergic receptor in human T cells infiltrating inflammatory bowel disease. *Laboratory Investigation*, vol.78(11): 1375–1383.
  31. Giannattasio G, Ohta S, Boyce J R, *et al.* 2011, The purinergic G protein-coupled receptor 6 inhibits effector T cell activation in allergic pulmonary inflammation. *Journal of Immunology*, vol.187(3): 1486–1495.  
<http://dx.doi.org/10.4049/jimmunol.1003669>
  32. Tsukimoto M, Tokunaga A, Harada H, *et al.* 2009, Blockade of murine T cell activation by antagonists of P2Y<sub>6</sub> and P2X<sub>7</sub> receptors. *Biochemical Biophysical Research Communication*, vol.384(4): 512–518.  
<http://dx.doi.org/10.1016/j.bbrc.2009.05.011>
  33. Inaba K, Inaba M, Romani N, *et al.* 1992, Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. *Journal of Experimental Medicine*, vol.176(6): 1693–1702.  
<http://dx.doi.org/10.1084/jem.176.6.1693>
  34. Ben Addi A, Lefort A, Hua X, *et al.* 2008, Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A(2B) receptor. *European Journal of Immunology*, vol.38(6): 1610–1620.  
<http://dx.doi.org/10.1002/eji.200737781>
  35. Norbury C C, 2006, Drinking a lot is good for dendritic

- cells. *Immunology*, vol.117(4): 443–451.  
<http://dx.doi.org/10.1111/j.1365-2567.2006.02335.x>
36. Burgdorf S, Kautz A, Böhnert V, *et al.* 2007, Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. *Science*, vol.316(5824): 612–616.  
<http://dx.doi.org/10.1126/science.1137971>
37. Marteau F, Communi D, Boeynaems J M, *et al.* 2004, Involvement of multiple P2Y receptors and signaling pathways in the action of adenine nucleotides diphosphates on human monocyte-derived dendritic cells. *Journal of Leukocyte Biology*, vol.76(4): 796–803.  
<http://dx.doi.org/10.1189/jlb.0104032>
38. Wilkin F, Duhant X, Bruyys C, *et al.* 2001, The P2Y<sub>11</sub> receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells. *Journal of Immunology*, vol.166(12): 7172–7177.  
<http://dx.doi.org/10.4049/jimmunol.166.12.7172>
39. Wilkin F, Stordeur P, Goldman M, *et al.* 2002, Extracellular adenine nucleotides modulate cytokine production by human monocyte-derived dendritic cells: dual effect on IL-12 and stimulation of IL-10. *European Journal of Immunology*, vol.32(9): 2409–2417.  
[http://dx.doi.org/10.1002/1521-4141\(200209\)32:9%3C2409::AID-IMMU2409%3E3.0.CO;2-H](http://dx.doi.org/10.1002/1521-4141(200209)32:9%3C2409::AID-IMMU2409%3E3.0.CO;2-H)
40. Müller T, Robaye B, Vieira R P, *et al.* 2010, The purinergic receptor P2Y<sub>2</sub> receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation. *Allergy*, vol.65(12): 1545–1553.  
<http://dx.doi.org/10.1111/j.1398-9995.2010.02426.x>
41. Pizzirani C, Ferrari D, Chiozzi P, *et al.* 2007, Stimulation of P2 receptors causes release of IL-1 $\beta$ -loaded microvesicles from human dendritic cells. *Blood*, vol.109: 3856–3864.  
<http://dx.doi.org/10.1182/blood-2005-06-031377>
42. Weber F C, Esser P R, Müller T, *et al.* 2010, Lack of the purinergic receptor P2X<sub>7</sub> results in resistance to contact hypersensitivity. *Journal of Experimental Medicine*, vol.207(12): 2609–2619.  
<http://dx.doi.org/10.1084/jem.20092489>
43. Cunningham A F, Khan M, Ball J, *et al.* 2004, Responses to the soluble flagellar protein FliC are Th2, while those to FliC on *Salmonella* are Th1. *European Journal of Immunology*, vol.34(11): 2986–2995.  
<http://dx.doi.org/10.1002/eji.200425403>